In the largest study so far of CAR T cells in patients with solid tumors, autologous CLDN18.2-targeting CAR T cell therapy was well tolerated in patients with advanced CLDN18.2-positive gastrointestinal cancers, with an overall response rate of 42.2% and a disease control rate of 91.1%.
- Changsong Qi
- Chang Liu
- Lin Shen
